Subscribe to the UniQuest newsletter Subscribe

Register your interest for UniQuest's 2027 Research Commercialisation Workshop Register now

AG/Food Investor Fund Pitch Event Expression of Interest open now

Latest news

November 10, 2026

National clinical trial for Australian-developed MND therapy

An Australian-developed MND therapy based on more than 25 years of UQ research is advancing to a 75-participant Phase 2 clinical trial. Developed at UQ’s Queensland Brain Institute and advanced by UniQuest-founded NuNerve, NUN-004 aims to protect motor neurons and support nerve repair.
September 23, 2026

UQ innovators progress therapies to tackle dementia

Two UQ research teams supported by UniQuest have secured $4 million in CUREator+ funding to advance potential new therapies for Alzheimer’s disease and dementia, accelerating the journey from laboratory discovery towards clinical development.
July 1, 2025

The BIO2025 Diaries

The UniQuest teams' key insights into evolving trends in therapeutic development and what's piquing pharma interest at the BIO International Convention held in June in Boston, USA.
October 9, 2024

Aussie avocado technology to hit Latin America

A tissue-culture propagation technology developed at The University of Queensland to grow hundreds of plants from a single cutting is set to bolster avocado production across Latin America to meet growing demand.
May 24, 2023

Recognition for promising UQ biomedical research

A promising treatment for inflammatory bowel disease and a pre-clinical drug candidate for a devastating neurological condition are among four University of Queensland (UQ) research projects to receive support from Australia’s national biotech incubator – CUREator.
September 14, 2022

BTB initiative wraps up with impact

The successful Medical Research Future Fund (MRFF) funded Biomedical Translation Bridge (BTB) Program has successfully concluded after supporting 21 therapeutic and medical device projects towards commercialisation.
September 23, 2021

Drug repurposing is no panacea in race to treat COVID-19

Drug repurposing is no quick fix for developing new treatments for disease, including COVID-19, and there are inherent dangers and pitfalls with translating drugs such as chloroquine, hydroxychloroquine, ivermectin and similar compounds to treat COVID-19, say a team of experts.